Pharmacological options for the protection of ovarian function in patients undergoing chemotherapy

Figures & data

Table I: The incidence of ovarian failure in different studies with and without gonadotrophin-releasing hormone agonist administration

References	GnRH agonist (%)	Control (%)	Follow-up (years)
Waxman et al^35	50.0	67.0	2.3
Blumenfeld et al^36	0.0	66.0	-
Pereyra Pacheco	0.0	100.0	< 5.0
et al^37
Blumenfeld and	7.0	54.0
Eckman^38
Franke, Smit and	20.0	-	< 1.0
Vermes^39
Dann et al^40	0.0	17.0	5.3
Somers et al^41	5.0	30.0	-
Elis et al^42	0.0	8.7	-
Del Mastro et al^43	3.0	-	1.0
Recchia et al^44	33.0		6.3
Giuseppe et al^45	0.0	47.0	2.4
Castelo-Branco	7.0	77.0	-
et al^46
Blumenfeld et al^24	3.0	37.0	8.0
Huser et al^47	21.0	71.0	1.0
Badawy, Elnashar,	11.0	67.0	< 1.0
El-Ashry, Shahat^48
Gerber et al^49	0.0	0.0	2.0

GnRH: gonadotrophin-releasing hormone

Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol. 1987;19(2):159–162.

 PubMed Web of Science ®Google Scholar

Blumenfeld Z, Shapiro D, Shteinberg M, et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000;9(6):401–405.

 PubMed Web of Science ®Google Scholar

Pereyra Pacheco B, Mendez-Ribaz JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol. 2001;81(3):391–397.

 PubMed Web of Science ®Google Scholar

Blumenfeld Z, Eckman E. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr. 2005;34:40–43.

 PubMedGoogle Scholar

Franke HR, Smit WM, Vermes I. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin’s disease undergoing chemotherapy. Gynecol Endocrinol. 2005;20(5):274–278.

 PubMed Web of Science ®Google Scholar

Dann EJ, Epelbaum R, Avivi I, et al. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod. 2005;20(8):2247–2249.

 PubMed Web of Science ®Google Scholar

Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005;52(9):2761–2767.

 PubMed Web of Science ®Google Scholar

Elis A, Tevet A, Yerushalmi R, et al. Fertility status among women treated for aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma. 2006;47(4):623–627.

 PubMed Web of Science ®Google Scholar

Del Mastro L, Catzeddu T, Boni I, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006;17(1):74–78.

 PubMed Web of Science ®Google Scholar

Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106(3):514–523.

 PubMed Web of Science ®Google Scholar

Giuseppe L, Attilio G, Eduordo DN, et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 2007;12(2):141–147.

 PubMed Web of Science ®Google Scholar

Castelo-Branco C, Nomdedeu B, Camus A, et al. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin’s disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril. 2007;87(3):702–705.

 PubMed Web of Science ®Google Scholar

Blumenfeld Z, Avivi I, Eckman A, et al. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril. 2008;89(1):166–173.

 PubMed Web of Science ®Google Scholar

Huser M, Crha I, Ventruba P, et al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod. 2008;23(4):863–868.

 PubMed Web of Science ®Google Scholar

Badawy A, Elnashar S, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91(3):694–697.

 PubMed Web of Science ®Google Scholar

Gerber B, von Minkwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334–2341.

 PubMed Web of Science ®Google Scholar